Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion ...

Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...

Galapagos (0JXZ – Research Report) received a Sell rating and a €22.00 price target from Barclays analyst Emily Field today. The company’s ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

Combining baricitinib with narrowband UVB phototherapy led to significant repigmentation and enhanced quality of life in ...